title: Risk Factors for Febrile Neutropenia in Children With Solid Tumors Treated With Cisplatin-based Chemotherapy.
abstract: Febrile neutropenia (FN) is a common and potentially fatal adverse drug reaction of cisplatin-based chemotherapy (CDDPBC) in pediatric patients. Hence, the aim of this study was to determine the incidence and independent risk factors for FN in pediatric patients with solid tumors treated with CDPPBC. Cohort integration was performed in the first cycle of chemotherapy with CDDPBC and patients were followed up to 6 months after the last cycle. FN was defined according to the Common Terminology Criteria for Adverse Events. Relative risks were calculated with confidence intervals at 95% (95% CI) to determine FN risk factors. Multiple logistic regression was performed to identify independent risk factors. One hundred and thirty-nine pediatric patients (median age 7.4 y, range 0.08 to 17 y) were included in the study. FN incidence was 62.5%. Independent risk factors for FN were chemotherapy regimens including anthracyclines (odds ratio [OR]=19.44 [95% CI, 5.40-70.02), hypomagnesaemia (OR=8.20 [95% CI, 1.81-37.14]), and radiotherapy (OR=6.67 [95% CI, 1.24-35.94]). It is therefore concluded that anthracyclines-containing regimens, hypomagnesaemia, and radiotherapy are independent risk factors for FN in patients receiving CDDPBC.
authors.affiliation: *Facultad de Estudios Superiores Zaragoza ¶Faculty of Medicine, Universidad Nacional Autónoma de México †Clinical Epidemiology Unit, Hospital Infantil de México Federico Gómez ‡Pharmacology Department, Centro de Investigación y Estudios Avanzados del Instituto Politécnico Nacional §Onco-Hematology Department, Hospital Infantil de México Federico Gómez ∥Oncology Department, Hospital de Pediatría "Dr. Silvestre Frenk Freud" #Coordination of Health Research, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
authors.forename: Osvaldo D
authors.initials: OD
authors.lastname: Castelán-Martínez
authors.forename: Felipe
authors.initials: F
authors.lastname: Rodríguez-Islas
authors.forename: Jessica L
authors.initials: JL
authors.lastname: Vargas-Neri
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Palomo-Colli
authors.forename: Enrique
authors.initials: E
authors.lastname: López-Aguilar
authors.forename: Patricia
authors.initials: P
authors.lastname: Clark
authors.forename: Gilberto
authors.initials: G
authors.lastname: Castañeda-Hernández
authors.forename: Rodolfo
authors.initials: R
authors.lastname: Rivas-Ruiz
mesh_terms: D000293:Adolescent; D018943:Anthracyclines / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D059248:Chemoradiotherapy / Q000009:adverse effects / Q000379:methods; D002648:Child; D002675:Child, Preschool; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D015331:Cohort Studies; D064147:Febrile Neutropenia / Q000139:chemically induced* / Q000453:epidemiology; D005260:Female; D006801:Humans; D015994:Incidence; D007223:Infant; D007231:Infant, Newborn; D008274:Magnesium / Q000097:blood; D008297:Male; D009369:Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D012189:Retrospective Studies; D012307:Risk Factors
chemical_list: D018943:Anthracyclines; D008274:Magnesium; D002945:Cisplatin